Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04506125
Other study ID # 29BRC20.0086
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 18, 2021
Est. completion date August 29, 2022

Study information

Verified date July 2023
Source University Hospital, Brest
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Anemia is common in oncology. Up to three-quarters of cancer patients are exposed to an episode of anemia. In oncology surgery, perioperative bleeding is a major risk factor for anemia. Indeed, 13 to 40% of patients are transfused in perioperative oncologic surgery. There is an association between anemia and prognosis. Several epidemiological studies have shown a strong association between anemia and altered quality of life. In oncology cohort studies, anemic patients had a significantly lower quality of life compared to patients without anemia. In non-cardiac surgery, preoperative anaemia was significantly associated with post-operative mortality. There is also an association between preoperative anaemia and the occurrence of post-operative complications. In oncology surgery, cohort studies conducted in colorectal surgery and neurosurgery found an association between the occurrence of perioperative anemia and post-operative morbidity and mortality. The optimal transfusion strategy is unknown in oncology patients. Several multicentre randomised trials, conducted in resuscitation patients or in perioperative settings, have compared a "restrictive" to a "liberal" transfusion strategy. These studies did not show a superiority of one strategy over another on patient outcomes but a lower exposure to red blood cell concentrates in patients transfused with the restrictive transfusion strategy. Thus, the French High Authority for Health (HAS) has adopted a haemoglobin level of 7 g/dl as the transfusion threshold for any transfusion of red blood cell concentrate carried out in the operating theatre and in intensive care in the absence of special cases such as the presence of acute coronary syndrome. For oncology patients, no recommendation could be made due to the lack of evidence-based literature and the optimal transfusion strategy for these patients remains unknown. Only 2 monocentric trials performed in oncology (critical care and perioperative) suggest a benefit of a liberal strategy (transfusion for a haemoglobin level < 9 g/dl) on the short-term vital prognosis, but these studies suffer from numerous limitations leaving the question unresolved. Before conducting a large phase III trial, a pilot study is needed to validate the methodology of this multicentre clinical trial and to assess its feasibility.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date August 29, 2022
Est. primary completion date August 29, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age > 18 years old - Anticipated or proven admission to immediate postoperative resuscitation after scheduled or emergency oncology surgery, for the removal of a neoplastic lesion among the following surgical procedures: - Visceral surgery: Hepatectomy, duodenopancreatectomy, gastrectomy, esophagectomy, colectomy - Urological surgery: Radical prostatectomy, cystectomy, nephrectomy. - Gynaecological surgery: Ovariectomy, hysterectomy, mastectomy, pelvectomy - Thoracic surgery: Pneumonectomy, lobectomy - ENT Surgery: Total laryngectomy, pharyngectomy, glossectomy - Spinal surgery: corporectomy wherever it is performed. - Hemoglobin level < 9.5 g/dl between the day before surgery (D-1) and discharge from resuscitation at no more than 30 days postoperatively Exclusion Criteria: - - Myocardial infarction and/or unstable angina in the 4 weeks prior to surgery - Refusal to participate in the study - Minor patient (age < 18 years) - Refusal to transfuse red blood cell concentrates (Jehovah's Witness) - Pregnant or breastfeeding women - Patients under guardianship or curatorship

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Haemoglobin 9.5 g/dL
transfusion of red blood cell concentrate if the haemoglobin level is less than 9,5 g/dL
Haemoglobine 7.5g/dL
transfusion of red blood cell concentrate if the haemoglobin level is less than 7,5 g/dL

Locations

Country Name City State
France CHU d'Angers Angers
France CHRU de Brest Brest

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Methodology of the pilot study The difference in mean hemoglobin levels during the perioperative period up to 30 days postoperatively between the two groups will be assessed up to 30 days
Secondary Epidemiological data of the pilot study The percentage of patients with oncologic surgery admitted to intensive care unit requiring transfusion of red blood cell concentrates eerioperatively among aatients with oncologic surgery admitted to intensive care unit will be assessed up to 90 days
Secondary Epidemiological data of the pilot study Percentage of eligible patients included in the study will be assessed up to 90 days
Secondary Epidemiological data of the pilot study Delay between surgery and randomization will be assessed up to 90 days
Secondary Epidemiological data of the pilot study Percentage of protocol violations in each group will be assessed up to 90 days
Secondary Epidemiological data of the pilot study Average number of erythrocyte concentrates delivered to each group intraoperatively, in intensive care and during hospitalization will be assessed up to 90 days
Secondary Epidemiological data of the pilot study Post-operative complications, occurring between surgery and the 30th day after surgery or before discharge from hospital will be assessed up to 90 days
Secondary Adverse Reaction Monitoring To compare the occurrence of transfusion-related adverse events in each group up to 30 days
Secondary Evaluation of the functional status Test functional status assessment at 30 days postoperatively using the World Health Organization Disability Assessment Schedule (WHODAS) questionnaire.
This questionnaire asks about difficulties due to health/mental health conditions. Health conditions include diseases or illnesses, other health problems that may be short or long lasting, injuries, mental or emotional problems, and problems with alcohol or drugs. The patient must think back over the past 30 days and answer the questions thinking about how much difficulty you had doing the following activities.
up to 30 days
Secondary Evaluation of the functional status after surgery ans anesthesia Test functional status assessment at 30 days postoperatively using the Quality of recovery questionnaire.
The Quality of Recovery-15 (QoR-15) is a psychometrically tested and validated questionnaire.
The QoR-15 was psychometrically evaluated using data collected from patients who responded at all four time intervals.This included: Acceptability and Feasibility; Validity; Reliability; Responsiveness
up to 30 days
Secondary Monitoring of the quality of the study's execution Compare the percentage of protocol violations in the 2 groups up to 30 days
See also
  Status Clinical Trial Phase
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03341338 - Genes-in-Action - Hepcidin Regulation of Iron Supplementation
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Not yet recruiting NCT06309641 - Methemoglobinemia Following Intravenous Iron Treatment
Completed NCT03822884 - Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers Phase 1
Completed NCT02912533 - A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02912494 - A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02603250 - Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda N/A
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Withdrawn NCT01934842 - A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate N/A
Completed NCT02310113 - Transfusion and Skeletal Muscle Tissue Oxygenation N/A
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Terminated NCT01535781 - Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced? N/A
Completed NCT01432717 - Study of ACE-536 in Healthy Postmenopausal Women Phase 1